Avalon Globocare Corp
NASDAQ:ALBT
Net Margin
Avalon Globocare Corp
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
A
|
Avalon Globocare Corp
NASDAQ:ALBT
|
4m USD |
-647%
|
|
| US |
|
CVS Health Corp
NYSE:CVS
|
77.9B USD |
1%
|
|
| US |
C
|
Cigna Group
XMUN:CGN
|
67.7B EUR |
2%
|
|
| US |
|
Cigna Corp
NYSE:CI
|
70.2B USD |
2%
|
|
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
26.1B EUR |
3%
|
|
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
23.2B EUR |
2%
|
|
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
21.4B USD |
6%
|
|
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
19B USD |
9%
|
|
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
13.1B EUR |
3%
|
|
| US |
|
Hims & Hers Health Inc
NYSE:HIMS
|
14.2B USD |
9%
|
|
| US |
|
DaVita Inc
NYSE:DVA
|
10.7B USD |
7%
|
Avalon Globocare Corp
Glance View
Avalon GloboCare Corp. is a holding company, which engages in the development of biotechnology and the provision of healthcare services. The company is headquartered in Freehold, New Jersey and currently employs 5 full-time employees. The company went IPO on 2016-02-22. The firm is focused on the fields of cellular immunotherapy, including CAR-T/NK; exosome technology (ACTEX), and COVID-19-related vaccine and therapeutics through its subsidiaries. The company operates through two business segments: real property operating segment and medical related consulting services segment. The firm also provides strategic advisory and outsourcing services to facilitate and improve its clients’ growth and development, as well as competitiveness in healthcare and CellTech industry markets. Its downstream medical team and facility consists of affiliated hospital networks and experts specialized in hematology, oncology, cellular immunotherapy, hematopoietic stem/progenitor cell transplant, as well as regenerative therapeutics. Its clinical programs include AVA-001, ACTEX, FLASH-CAR, and AVA-Trap.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Avalon Globocare Corp's most recent financial statements, the company has Net Margin of -647.1%.
You don't have any saved screeners yet